Scaled availability of point-of-care G6PD diagnostic kits for rural tropical regions, which suffer the largest burden of vivax malaria, will protect individuals vulnerable to 8-aminoquinolone drug-induced adverse events and enable individuals with normal G6PD levels to receive curative treatment [10]. Here, G6PD is linked to Plasmodium vivax malaria.